Current and Emerging Treatments for Advanced Cutaneous Melanoma: Pharmacist Pearls

NOTE: If you attended this live CE activity AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-0000-21-103-L01-P), you are ineligible to also receive CE credit for this home-study activity.  

Activity Description

Melanoma is the fifth most common cancer in the United States and the incidence is increasing. Management strategies depend on the staging at diagnosis, and although most cases are diagnosed at an earlier stage, advanced cutaneous melanoma is far more aggressive and requires quick intervention. Since 2010, nearly a dozen new treatments/treatment regimens for melanoma have been approved by the FDA, including 4 systemic immunotherapy treatments/combinations, single-agent BRAF inhibitors, combination BRAF/MEK inhibitor regimens, and 1 intralesional immunotherapy involving a modified oncolytic herpes virus.

Pharmacists, including clinical, oncology, and specialty pharmacists, play an expanded role in the treatment and management of patients with melanoma. This activity will focus on individualized treatment selection, mechanisms of action and drug targets, adverse effect profiles, management, and access will help ameliorate gaps in clinical knowledge for pharmacists who find it challenging to stay up to date on the latest data.

Learning Objectives

The target audience for this activity includes pharmacists, including clinical and health-system pharmacists, board-certified oncology pharmacists, specialty pharmacy and managed care professionals, and other pharmacists responsible for the care and management of patients with advanced melanoma. At the completion of this activity, the participant will be able to:

  • Discuss individualized treatment strategies using biomarkers, clinical characteristics, and patient preferences for the management of melanoma.
  • Examine current and emerging therapeutic treatments for advanced melanoma.
  • Describe strategies to proactively develop management plans for adverse events associated with targeted and immunotherapeutic melanoma therapies.


Heather Armbruster, PharmD, BCOP
Specialty Practice Pharmacist, Melanoma and Neuroendocrine Tumors
The James Cancer Hospital at The Ohio State University
Columbus, Ohio

Jessica Davis, PharmD, BCOP, CPP
Clinical Pharmacist Coordinator, Adult Hematology/Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

CE Accreditation

Release Date: 4-22-2021
Expiration Date: 5-13-2022


ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-21-103-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.


It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Armbruster has received other financial or material support from Merck. Dr. Davis has received consulting fees from Exelixis, Inc. and Regeneron Pharmaceuticals, Inc.; received fees for non-CME/CE services from Exelixis, Inc. ProCE Staff have no relevant conflicts of interest to report. Potential conflicts of interest were resolved with a peer review process.


This activity is supported by an educational grant from Merck Sharp & Dohme Corp.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.